Volume 1, Number 3, September 2000

The involvement of AT₂-receptor in the antithrombotic effect of losartan in renal hypertensive rats
Ewa Chabielska, Tomasz Matys, Iwona Kucharewicz, Dariusz Pawlak, Roland Rólkowski, Wlodzimierz Buczko

In previous studies, we have shown that losartan possesses nitric oxide-dependent antithrombotic properties in various models of hypertension in rats. It was demonstrated that stimulation of AT₂-receptors plays an important role in the pharmacological effects of AT₁-receptor antagonists. Thus, in this study, we examine the participation of AT₂-receptors in the antithrombotic action of losartan in renal hypertensive rats on venous thrombosis induced by a two-hour ligation of the vena cava. Losartan administration (30 mg/kg, p.o.) resulted in a marked decrease in thrombus weight (by 85%, p<0.001). PD123319, an AT₂-receptor antagonist (10 mg/kg, i.v.), administered concomitantly with losartan, abolished its antithrombotic effect, whilst it had no influence on thrombus weight when given alone. A significant decrease in systolic blood pressure was observed in animals given losartan. PD123319 administration did not abolish this action of losartan and did not alter blood pressure when given alone. No changes in prothrombin time, activated partial thromboplastin time, or euglobulin clot lysis time were observed in animals administered losartan and/or PD123319. Similarly, primary haemostatics evaluated by bleeding time and platelet count did not change in any group of rats. In conclusion, we have shown that AT₂-receptor stimulation is involved in the antithrombotic action of losartan in renal hypertensive rats.

JRAAS 2000;1:263-267.

View full PDF article (open in new window)
Email this article

Right click on this DOI link and copy link to cite this article (What is a DOI link?)